Cross-priming in cancer immunology and immunotherapy
Cytotoxic T cell immune responses against cancer crucially depend on the ability of a subtype of professional antigen-presenting cells termed conve…
Tag: Cancer immunotherapy
Mapping T cell dynamics to molecular profiles through behavior-guided transcriptomics
The rise of cellular immunotherapy for cancer treatment has led to the utilization of immune oncology cocultures to simulate T cell interactions wi…
A functional single-cell metabolic survey identifies Elovl1 as a target to enhance CD8+ T cell fitness in solid tumours
Reprogramming T cell metabolism can improve intratumoural fitness. By performing a CRISPR/Cas9 metabolic survey in CD8+ T cells, we iden…
Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial
Historically, the treatment of patients with advanced stage or recurrent endometrial cancer included paclitaxel plus carboplatin. Immunotherapy in …
A unified deep framework for peptide–major histocompatibility complex–T cell receptor binding prediction
Antigen peptides that are presented by a major histocompatibility complex (MHC) and recognized by a T cell receptor (TCR) have an essential role in…
Immunogenomic determinants of exceptional response to immune checkpoint inhibition in renal cell carcinoma
Immune checkpoint inhibitors can lead to ‘exceptional’, durable responses in a subset of persons. However, the molecular basis of exceptional r…